Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

@inproceedings{Staudt2018TargetingOS,
  title={Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance},
  author={Dilana Staudt and Heather C Murray and Tabitha McLachlan and Frank Alvaro and Anoop K Enjeti and Nicole M Verrills and Matthew D Dun},
  booktitle={International journal of molecular sciences},
  year={2018}
}
The identification of recurrent driver mutations in genes encoding tyrosine kinases has resulted in the development of molecularly-targeted treatment strategies designed to improve outcomes for patients diagnosed with acute myeloid leukemia (AML). The receptor tyrosine kinase FLT3 is the most commonly mutated gene in AML, with internal tandem duplications within the juxtamembrane domain (FLT3-ITD) or missense mutations in the tyrosine kinase domain (FLT3-TKD) present in 30⁻35% of AML patients… CONTINUE READING
7
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 193 REFERENCES

Genomic Classification and Prognosis in Acute Myeloid Leukemia.

  • The New England journal of medicine
  • 2016
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Emergence of polyclonal FLT3 tyrosine kinase domain mutations during sequential therapy with sorafenib and sunitinib in FLT3-ITD-positive acute myeloid leukemia.

  • Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2013
VIEW 10 EXCERPTS
HIGHLY INFLUENTIAL